5e
eb
Dr. Shashaty's career is focused on epidemiologic and translational research studies of the risks for and mechanisms of acute organ dysfunction, primarily acute kidney injury (AKI), in critical illness and populations.
8
2cf
Dr. Shashaty has formal training in the clinical practice of pulmonary and critical care medicine, biostatistical and epidemiologic methods, and protein, gene expression, and genomic analyses of human biospecimens. He is the principal investigator for the Lung Transplant Outcomes Group–Acute Kidney Injury (LTOG-AKI) study, a multicenter prospective cohort of lung transplant recipients (n>1800) designed to study the clinical and molecular epidemiology of post-lung transplant AKI. The primary focus of this study is to determine clinical characteristics and novel blood and urine biomarkers that are useful for AKI prediction and may provide insight into molecular mechanisms of AKI after transplantation.
8
1cc
Dr. Shashaty is also the principal investigator for the ongoing Penn Trauma Organ Dysfunction Study (PETROS), a cohort of critically ill trauma patients (n>1300), and a co-investigator in Penn’s Molecular Epidemiology of Severe Sepsis in the ICU (MESSI) cohort, for which he leads studies of AKI. Current areas of study in these cohorts include circulating cell-free DNA as a mechanistic contributor to AKI and ARDS as well as novel phenotypes of AKI.
65
189
Dr. Shashaty is specialty-trained in internal medicine, pulmonary diseases, and critical care medicine. He is an attending physician at the Hospital of the University of Pennsylvania (HUP), with the majority of his clinical time spent in the medical intensive care unit. He also attends on and is the service lead for the Critical Care Outreach and Procedure Service (CCOPS).
8
196
From 2017-24, Dr. Shashaty served as the Rapid Response Medical Director at HUP. In this capacity, he worked with a multidisciplinary team to provide oversight, design and conduct training, and pursue quality improvement initiatives in the areas of clinical emergencies and management of cardiac arrest. He played a central role in adapting HUP's clinical emergencies team to the COVID-19 pandemic.
8
103
Dr. Shashaty is actively engaged in teaching fellows, house officers, medical students, and advanced practice providers through both HUP clinical services, classes at the Perelman School of Medicine, and training programs at the Penn School of Nursing.
1a
29
23
Selected Publications
19d
Bennett RM, Housel KC, Jones TK, Giannini HM, Emre G, Esperanza M, Turner A, Ittner C, Shashaty MGS, Feng R, Anderson MR, Weissman GE, Meyer NJ, Christie JD, Reilly JP.: Two Physiologic Latent Classes of Acute Hypoxemic Respiratory Failure in Sepsis Are Distinguished by Lung Mechanics and Gas Exchange. Crit Care Explor 7: e1314, Sep 2025.
149
Jones TK, Reilly JP, Anderson BJ, Miano TA, Karanam B, Ittner CAG, Shashaty MGS, Feng R, Meyer NJ.: Soluble Fms-Like Tyrosine Kinase-1 Associates With Risk of Acute Respiratory Distress Syndrome and Mortality in Sepsis. Crit Care Explor 7: e1294, Aug 2025.
15e
Ronner L, Giannini HM, Miano TA, Ittner CAG, Turner AP, Dunn TG, Agyekum RS, Dasgupta A, West K, Jones TK, Shashaty MGS, Reilly JP, Meyer NJ.: Parsimonious Subphenotyping Algorithms Perform Differently in Patients With Sepsis and Hematologic Malignancy. Crit Care Med Jul 2025.
15d
Dasgupta A, Jones TK, Giannini H, Bennett R, Emre G, Ittner CAG, Turner A, Esperanza M, Housel K, Miano T, Erlich M, Anderson BJ, Shashaty MGS, Meyer NJ, Reilly JP.: Identifying a unique signature of sepsis in patients with pre-existing cirrhosis. Crit Care 29: 199, May 2025.
112
Miano TA, Brotman CHW, Scheetz MH, Shashaty MGS.: Effect of Pseudonephrotoxicity on Apparent Acute Kidney Injury Incidence and Severity: A Simulation Study. Clin J Am Soc Nephrol 20: 866-868, Dec 2024.
16f
Miano TA, Zuppa AF, Feng R, Griffiths S, Kalman L, Oyster M, Cantu E, Yang W, Diamond JM, Christie JD, Scheetz MH, Shashaty MGS.: Development and validation of a population pharmacokinetic model to guide perioperative tacrolimus dosing after lung transplantation. JHLT Open 6: 100134, Aug 2024.
23f
Schneider ALC, Ginestra JC, Kerlin MP, Shashaty MGS, Miano TA, Herman DS, Mitchell OJL, Bennett R, Moffett AT, Chandler J, Kalanuria A, Faraji Z, Bishop NS, Schmid B, Chen AT, Bowles KH, Joseph T, Kohn R, Kelz RR, Anesi GL, Kumar M, Friedman AB, Vail E, Meyer NJ, Himes BE, Weissman GE.: The Complete Inpatient Record Using Comprehensive Electronic Data (CIRCE) project: A team-based approach to clinically validated, research-ready electronic health record data. Learn Health Syst 9: e10439, Jun 2024.
148
Bennett RM, Reilly JP, Diamond JM, Cantu E, Shashaty M, Benvenuto L, Singer JP, Palmer SM, Christie JD, Anderson MR.: Body mass index and mortality following primary graft dysfunction: A Lung Transplant Outcomes Group study. JHLT Open 5: 100107, May 2024.
222
Diamond JM, Anderson MR, Cantu E, Clausen ES, Shashaty MGS, Kalman L, Oyster M, Crespo MM, Bermudez CA, Benvenuto L, Palmer SM, Snyder LD, Hartwig MG, Wille K, Hage C, McDyer JF, Merlo CA, Shah PD, Orens JB, Dhillon GS, Lama VN, Patel MG, Singer JP, Hachem RR, Michelson AP, Hsu J, Russell Localio A, Christie JD.: Development and validation of primary graft dysfunction predictive algorithm for lung transplant candidates. J Heart Lung Transplant 43(4): 633-641, Apr 2024.
10d
Reilly JP, Shashaty MGS, Miano TA, Giannini HM, Jones TK, Ittner CAG, Christie JD, Meyer NJ.: ABO Histo-Blood Group and the von Willebrand Factor Axis in Severe COVID-19. CHEST Crit Care Dec 2023.
2c
7
1d
2c
back to top
26
Last updated: 10/21/2025
34
The Trustees of the University of Pennsylvania
c
1f
8
43
